1.285
price down icon5.17%   -0.07
after-market Handel nachbörslich: 1.32 0.035 +2.72%
loading
Schlusskurs vom Vortag:
$1.355
Offen:
$1.26
24-Stunden-Volumen:
643.25K
Relative Volume:
0.38
Marktkapitalisierung:
$92.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-292.19M
KGV:
-0.283
EPS:
-4.54
Netto-Cashflow:
$-208.41M
1W Leistung:
-28.21%
1M Leistung:
-33.07%
6M Leistung:
-59.84%
1J Leistung:
-91.77%
1-Tages-Spanne:
Value
$1.21
$1.30
1-Wochen-Bereich:
Value
$1.21
$1.81
52-Wochen-Spanne:
Value
$1.21
$16.21

Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile

Name
Firmenname
Zentalis Pharmaceuticals Inc
Name
Telefon
(858) 263-4333
Name
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Name
Mitarbeiter
0
Name
Twitter
@ZentalisP
Name
Nächster Verdiensttermin
2025-03-26
Name
Neueste SEC-Einreichungen
Name
ZNTL's Discussions on Twitter

Vergleichen Sie ZNTL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ZNTL
Zentalis Pharmaceuticals Inc
1.285 92.28M 0 -292.19M -208.41M -4.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-12 Hochstufung Wedbush Underperform → Neutral
2024-06-20 Herabstufung UBS Buy → Neutral
2024-06-18 Herabstufung Jefferies Buy → Hold
2024-06-18 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-06-18 Herabstufung Wedbush Neutral → Underperform
2024-06-18 Herabstufung Wells Fargo Overweight → Equal Weight
2023-11-08 Herabstufung Wedbush Outperform → Neutral
2023-11-07 Herabstufung Leerink Partners Outperform → Market Perform
2022-07-12 Eingeleitet Cowen Outperform
2022-04-06 Eingeleitet Wells Fargo Overweight
2021-10-07 Fortgesetzt Jefferies Buy
2021-09-30 Eingeleitet Stifel Buy
2021-09-29 Eingeleitet Oppenheimer Outperform
2021-05-21 Eingeleitet UBS Buy
2021-01-20 Eingeleitet Wedbush Outperform
2020-09-29 Eingeleitet Cantor Fitzgerald Overweight
2020-08-27 Eingeleitet H.C. Wainwright Buy
2020-04-28 Eingeleitet Guggenheim Buy
2020-04-28 Eingeleitet Jefferies Buy
2020-04-28 Eingeleitet Morgan Stanley Overweight
2020-04-28 Eingeleitet SVB Leerink Outperform
Alle ansehen

Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten

pulisher
02:39 AM

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages - Defense World

02:39 AM
pulisher
Apr 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Zentalis Strengthens Team with $194,600 in Equity Incentives - Stock Titan

Apr 01, 2025
pulisher
Apr 01, 2025

Virtu Financial LLC Buys Shares of 24,973 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

Leerink Partnrs Issues Pessimistic Outlook for ZNTL Earnings - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Forecast for ZNTL Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

Leerink Partnrs Has Pessimistic Outlook of ZNTL Q1 Earnings - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Position Lifted by Charles Schwab Investment Management Inc. - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Wedbush Reiterates Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Zentalis Pharmaceuticals: Hold Rating Amid Clinical Progress and Financial Uncertainty - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Bank of New York Mellon Corp Sells 10,375 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Zentalis Pharmaceuticals Reports Progress and Financials - TipRanks

Mar 28, 2025
pulisher
Mar 27, 2025

Stifel maintains Buy on Zentalis stock with $9 target By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

H.C. Wainwright sets $10 target for Zentalis shares, maintains Buy By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 26, 2025

Zentalis Pharmaceuticals Inc Reports Annual EPS of -$2.33, Excee - GuruFocus

Mar 26, 2025
pulisher
Mar 26, 2025

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Zentalis Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

Zentalis Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250 MillionSEC Filing - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Zentalis Breakthrough: 35% Response Rate in Ovarian Cancer Trial Wins FDA Fast Track - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Zentalis Pharmaceuticals to Present Multiple Posters at the - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 - TradingView

Mar 25, 2025
pulisher
Mar 21, 2025

Zentalis Pharmaceuticals Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 20, 2025

Zentalis pharmaceuticals director Luke Walker buys $24,966 in stock - MSN

Mar 20, 2025
pulisher
Mar 19, 2025

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Buy Rating from HC Wainwright - The AM Reporter

Mar 19, 2025
pulisher
Mar 17, 2025

H.C. Wainwright maintains $10 target on Zentalis stock By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Zentalis Highlights Promising Azenosertib Data at SGO 2025 - TipRanks

Mar 17, 2025
pulisher
Mar 15, 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at - GlobeNewswire

Mar 15, 2025
pulisher
Mar 15, 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - MarketScreener

Mar 15, 2025
pulisher
Mar 15, 2025

Zentalis Announces Updated Clinical Data From Part 1b Of DENALI Trial Of Azenosertib In PROC - Nasdaq

Mar 15, 2025
pulisher
Mar 15, 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - TradingView

Mar 15, 2025
pulisher
Mar 15, 2025

Breakthrough: Zentalis Drug Achieves 35% Response Rate Against Hard-to-Treat Ovarian Cancer - Stock Titan

Mar 15, 2025
pulisher
Mar 11, 2025

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Has Been Trading Down. What Are The Prospects For The Future? - stocksregister.com

Mar 11, 2025
pulisher
Mar 09, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Brokerages - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

ZNTL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 03, 2025

How Zentalis Is Attracting Talent: Inside Their Latest Employee Compensation Package - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Zentalis Pharmaceuticals Announces Multiple Data - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - Yahoo Finance

Mar 03, 2025
pulisher
Feb 27, 2025

A company insider recently bought 20,000 shares of Zentalis Pharmaceuticals Inc [ZNTL]. Should You Buy? - Knox Daily

Feb 27, 2025
pulisher
Feb 25, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc.ZNTL - PR Newswire

Feb 25, 2025
pulisher
Feb 24, 2025

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

Feb 24, 2025
pulisher
Feb 24, 2025

Can Zentalis' Novel Cancer Drug Pipeline Impress at Two Elite Healthcare Conferences? - StockTitan

Feb 24, 2025
pulisher
Feb 23, 2025

Zentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on Tuesday - The AM Reporter

Feb 23, 2025
pulisher
Feb 22, 2025

Zentalis stock price target cut to $10 by H.C. Wainwright - MSN

Feb 22, 2025
pulisher
Feb 22, 2025

Zentalis pharmaceuticals officer sells $24,590 in stock - MSN

Feb 22, 2025
pulisher
Feb 21, 2025

Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently - Yahoo Finance

Feb 21, 2025
pulisher
Feb 20, 2025

Savant Capital LLC Acquires New Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Feb 20, 2025
pulisher
Feb 16, 2025

Zentalis stock plunges to 52-week low, hits $2.16 - MSN

Feb 16, 2025

Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):